• linkedin
  • Increase Font
  • Sharebar

    Report: Medicare Biosimilar Changes Could Save Billions

     

    “Biosimilars are not proving to be the cost savers once promised. There are not enough in the pipeline to create enough competition to create a significant difference for payers,” Goldberg told Drug Topics. “Generics are easier to switch than active proteins and future patients will be treated based on what works versus what is cheapest in the short term."

    CMS currently groups all biosimilars of a reference biologic under a single billing code and payment rate. Several groups have raised concerns that this policy undermines patient access to affordable biosimilar medicines and stifles the creation of a robust biosimilars market, according to AAM.

    “The current policy would cause biosimilars manufacturers to exit the market over time or decide not to enter at all, ultimately leading to higher costs for patients,” AAM said in a statement about the new report.

    “Shifting biosimilar reimbursement to unique codes increases patient access to more affordable, life-saving medicine and lowers prescription drug spending. This policy is critical to the development of a thriving biosimilars medicine market,” said Christine Simmon, Executive Director of the Biosimilars Council and Senior Vice President of Policy & Strategic Alliances at AAM. “This new report highlights the significant cost savings possible for both patients and payers if CMS implements this recommendation.”

    CMS has solicited comments on biosimilar reimbursements in its “Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2018 proposed rule,” and is expected to issue a final rule in late October, according to AAM.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available